Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Status:
Withdrawn
Trial end date:
2019-08-31
Target enrollment:
Participant gender:
Summary
Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing
surgery first and then receiving chemotherapy with or without radiation therapy. However, the
pancreatic cancer often comes back after this treatment. Therefore, the investigators are
studying whether giving treatment prior to surgery can help decrease the risk the cancer
returns.
Stereotactic Body Radiation Therapy (SBRT) is a highly focused type of radiation therapy
commonly used in the treatment of pancreatic cancer. This treatment has been shown to be safe
and effective for the preoperative treatment of pancreatic cancer. The purpose of this study
is to determine if combining an experimental drug, CCX872-B, with SBRT continues to be safe
and whether the combination treatment may be more effective at boosting the participant's
immune system's ability to kill the pancreatic cancer.